Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

32
5 Dividend Aristocrat ETFs for a Growing Retirement Income

2018-07-06 investorplace
The average retirement lasts for 18 years in the United States. Hence, when investing for retirement, investors need to consider how inflation will affect their income. Allocations into retirement stocks should be set with income in mind.
FOJCF O.PRF O CSL OPRF KMB KCDMY NNN.PRD NNN.PRF NNN.PRE FOJCY T KMB.WI TROW ABBV CFR MCD NNN ABBV

1
The Energy Companies Fighting For EV Charging Dominance

2018-07-04 oilprice
Jon LeSage is a California-based journalist covering clean vehicles, alternative energy, and economic and regulatory trends shaping the automotive, transportation, and mobility sectors.
RDS.B FOJCY RDS.A FOJCF RYDBF RDSB RDSA RYDAF

4
Is WisdomTree International MidCap Dividend Fund (DIM) a Hot ETF Right Now?

2018-06-19 zacks
Making its debut on 06/16/2006, smart beta exchange traded fund WisdomTree International MidCap Dividend Fund (DIM - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
SLFPF DIM FOJCY SL FOJCF NTOIF NTOIY SLFPY

98
5 Dividend Aristocrat ETFs for a Growing Retirement Income | InvestorPlace

2018-05-30 investorplace
The average retirement lasts for 18 years in the United States. Hence, when investing for retirement, investors need to consider how inflation will affect their income. Allocations into retirement stocks should be set with income in mind.
FOJCF O.PRF O CSL OPRF KMB KCDMY NNN.PRD NNN.PRF NNN.PRE FOJCY KMB.WI TROW ABBV CFR MCD NNN ABBV

0
Fortum Wins Russian Approval to Buy $4.5 Billion Stake in Uniper - Bloomberg

2018-04-28 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FOJCY UNPPY FOJCF UNPRF

90
German Energy Landscape Is Transformed Without German Banks - Bloomberg

2018-03-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
C.WSA DB BNPQY UNPRF C.WS.B RWEOY RWNEF CRZBF C.WS.A C.PRP C.PRU C.PRS CRZBY C C.PRL UNPPY C.PRJ FOJCF C.PRK BNPQF C.PRG C.PRC BNPZY RWNFF INNYY FOJCY C.PRPCL CGBBW

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 557955903